Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200896 | 0.81 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6202421 | 0.80 | GABRG2 (0.60) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL5264102 | 0.79 | GABRA1 (0.55) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6199891 | 0.79 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL18495676 | 0.78 | RAB9A (0.56) | MEN1KMT2ANPC1RAB9ACYP1A2 | |
| SCHEMBL2659517 | 0.78 | GABRA1 (0.47) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6198921 | 0.78 | FYN (0.51) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6202841 | 0.78 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA2PTGS2 | |
| SCHEMBL5262983 | 0.78 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA2GABRA5 | |
| SCHEMBL6201966 | 0.78 | GABRA1 (0.50) | GABRA1GABRG2GABRB3GABRA2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | claimed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | claimed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | claimed |
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | ALPL 3446/4885ALPI 3157/4885GABRA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.